摘要
目的:分析硼替佐米联合地塞米松治疗老年多发性骨髓瘤临床效果.方法:回顾性的选择2017年3月-2018年3月本院收治的100例老年多发性骨髓瘤患者,根据不同的治疗方案分成两组,对照组50例使用地塞米松、长春新碱、马法兰及吡柔比星治疗,研究组50例使用硼替佐米联合地塞米松治疗,对两组患者临床效果进行对比.结果:研究组临床总有效率为94.00%高于对照组(P<0.05);研究组不良反应发生率低于对照组16.00%(P<0.05).结论:老年多发性骨髓瘤患者使用硼替佐米联合地塞米松治疗临床效果显著,可减少不良反应发生率,同时能有效提高临床疗效,值得临床推广.
Objective:To analyze the clinical effect of bortezomib combined with dexamethasone in the treatment of elderly patients with multiple myeloma.Methods:A retrospective study of 100 elderly patients with multiple myeloma admitted to our hospital from March 2017 to March 2018.divided into two groups according to different treatment regimens.50 patients in the control group were treated with dexamethasone and vincristine.For the treatment of melphalan and pirarubicin,50 patients in the study group were treated with bortezomib plus dexamethasone,and the clinical effects of the two groups were compared.Results:The total effective rate of the study group was 94.00%higher than that of the control group(P<0.05).The incidence of adverse reactions in the study group was 16.00%lower than that of the control group(P<0.05).Conclusion:The clinical effect of bortezomib combined with dexamethasone in elderly patients with multiple myeloma is significant,which can reduce the incidence of adverse reactions,and can effectively improve the clinical efficacy,which is worthy of clinical promotion.
